UCN-01, a staurosporine inhibitor was the first inhibitor identified for both Chk1 and Chk2 and treatment with this compound lead to G2/M checkpoint deficiencies in IR-treated p53-deficient tumor cells (70). This evidence concerns the gene TP53 and neoplasm.